- 1 August 2019
1:00 pm - 2:00 pm
Thursday 1 AUGUST 2019, 1.00 PM
Auditorium, Level 6, Bancroft Building
FROM MOLECULAR PROFILING TO DRUG TARGETS, DIAGNOSTICS AND CELL BIOLOGY IN BREAST CANCER
Associate Professor Fares Al-Ejeh
QIMR Berghofer Medical Research Institute
Personalised Medicine is about giving the right treatment in the right way for the best outcome. Personalised Medicine relies on predicting the individual’s prognosis and the right treatments, as well as the availability of treatment options to choose from. These requirements are enabled by integrative research approaches in diagnostics and therapeutics, and approaches that bridge preclinical research to clinical research.
This talk will describe two current projects in our team. In the first project we are studying a gene expression signature which we developed from global transcriptome profiles of breast cancer as a prognostic and predictive test. Results from the validation studies using patient samples, and preclinical discovery of novel targets from within gene signature will be presented. The second project is a follow up from kinome profiling of primary breast tumours where we focused on an interesting kinase called the ‘big mitogen kinase 1’ or ERK5 in breast cancer. We discovered that ‘not-so-big’ splice variants of ERK5 are pathogenic and present diagnostic and therapeutic opportunities..
Associate Professor Al-Ejeh was awarded his Bachelor of Biotechnology then his PhD in 2005 from the University of Wollongong. His first post-doctoral position was funded by Oncaidia Ltd at the Royal Adelaide Hospital/Hanson Institute and led to developing Apomab®, an antibody for cancer diagnosis and therapy. Apomab® is anticipated to enter human trials in 2019/2020. He joined QIMR Berghofer in 2010 and established his own group, Personalised Medicine, in 2015. His track record includes four patents and two provisional patents in addition to more than 50 peer-reviewed publications. He has been developing diagnostics and targeted therapies against aggressive breast cancer using integrative and interdisciplinary approaches.